Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study. [PDF]
Shabnaz S +15 more
europepmc +1 more source
Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report. [PDF]
Wei Y, Yang X, Zheng Y, Zhang D.
europepmc +1 more source
Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China. [PDF]
Jiang W, Zhong W, Yu J, Tang Y, Guo Q.
europepmc +1 more source
Persistence to Multiple Myeloma Treatments Given at First Relapse-Results From the Australian Real-World OPTIMISE Study. [PDF]
Buescher F, Su S, Waterhouse B, Pinto C.
europepmc +1 more source
Response kinetics as a dynamic prognostic marker in patients with multiple myeloma. [PDF]
Cho HJ +21 more
europepmc +1 more source
Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma. [PDF]
Hanafy NAN, Kolemen S.
europepmc +1 more source
Collection of autologous CD34+ hematopoietic progenitor cells (HPC) in multiple myeloma: CD34 + cell collection yield in relation to molecular subtype, karyotype, and FISH results. [PDF]
Rjoop A +5 more
europepmc +1 more source
Development and validation of a sustainable UHPLC method for quantification and impurity profiling of carfilzomib. [PDF]
Patel H, Patel G, Chauhan P.
europepmc +1 more source
Treatment patterns and outcomes in patients with multiple myeloma in second relapse in Colombia (freedomm): a multicenter observational study. [PDF]
Quintero G +9 more
europepmc +1 more source

